Seres Therapeutics (MCRB) PT Raised to $38 at Canaccord Genuity, Following Drug Trial Results
Tweet Send to a Friend
Canaccord Genuity analyst John Newman ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
